MD PhD DDS BSc MSc FDSRCS
Dr Anna Patrikidou is a consultant in medical oncology and the Associate Medical Director at the Sarah Cannon Research Institute. Her specialist areas include Genitourinary oncology, Sarcoma and Neuro-oncology. She is one of the leading consultants in the country with regards to clinical trials and Immuno-oncology. Many trials she has worked on have a focus on early and late phase treatment options.
Dr Patrikidou is an Honorary Senior Clinical Lecturer at the UCL Cancer Institute and serves in an Honorary Consultant Oncologist post at University College London Hospital. She has an esteemed background in medical oncology, having carried out specialist training at Gustave Roussy Institute in Paris, France, and worked extensively on translational research. With training received as well in Greece, France and London (University College London, Institute of Cancer Research/Royal Marsden Hospital), her work in drug development is highly regarded.
Cancer immunotherapy became a primary focus when working as a consultant at the Geneva University Hospital, Switzerland. At this time Genito-urinary oncology, Neuro-oncology and Sarcoma oncology became main areas of interest, which have since enabled her to become one of the leading names in immunotherapy.
Experience in researching early and late phase clinical trials has seen Dr Patrikidou act as a Principal Investigator in several Phase I-IV oncology clinical trials across Europe, especially when looking at Genito-Urinary oncology and immuno-oncology.
Dr Patrikidou is a member of numerous research organisations such as the European Society of Medical Oncology ESMO and the European Organisation for Research and Treatment of Cancer EORTC (Genito-Urinary and Brain Tumour Groups). On the ESMO Annual Congress, she has acted as a Scientific Committee member.
Her research work has been presented at congresses across the world, and with a large number of works published, she is sought after as a key collaborator in many clinical and academic research projects.